alcium transport across the membrane of the cardiac sarcoplasmic reticulum (SR) plays an important role in the regulation of heart muscle contraction and relaxation. 1,2 The Ca 2+ -dependent ATPase SERCA2a is a 110-kDa protein of the SR membrane that is responsible for Ca 2+ uptake by this organelle and whose activity is modulated by phospholamban, another SR membrane protein. 3, 4 Phospholamban comprises 3 domains: an NH2-terminal cytoplasmic helical domain (domain Ia), a less structured cytoplasmic region (domain Ib), and a COOHterminal membrane helix (domain II). 5 The dephosphorylated form of phospholamban inhibits SERCA2a by reducing its apparent affinity for Ca 2+ . 6 Phosphorylation of phospholamban by cyclic AMP-dependent protein kinase reduces its inhibitory activity, and the consequent facilitation of the Ca 2+ -pumping activity of SERCA2a results in acceleration of relaxation and an increase in the contractility of heart muscle. 6, 7 This mechanism of SERCA2a regulation underlies the positive inotropic effect of -adrenergic receptor stimulation. 3 Indeed, cardiac performance in the absence of catecholamine stimulation is enhanced in phospholamban knockout mice, and cardiac function in these animals is not improved further in response to catecholamines. 8 Excessive inhibition of SERCA2a by a mutated phospholamban was shown to impair cardiac contractility and relaxation in mice, resulting in heart failure and cardiomyopathy. 4 In addition, ablation of phospholamban rescued the impaired cardiac function and morphological changes associated with dilated cardiomyopathy in mice that lack muscle LIM protein. 9 Phospholamban ablation has also been shown to rescue the impaired function of hearts that overexpress calsequestrin 10 or the 1-adrenergic receptor. 11 Removal of phospholamban-mediated inhibition of SERCA2a activity is thus a potential therapeutic option for treatment of heart failure and cardiomyopathy. 12, 13 Chemical cross-linking of purified proteins suggests that phospholamban binds directly to SERCA2a. 14 Site-specific mutagenesis and transient expression of the mutant proteins in heterologous cells have revealed that 3 sites of interaction in the cytoplasmic domains and membrane helices of both phospholamban and SERCA2a contribute to the inhibitory effect of the former on the latter. 4 Interaction of the transmembrane helices of the 2 proteins appears to play an especially prominent role in inhibition. 15 The transmembrane helix of phospholamban also mediates the formation of homopentamers that are stable in lipid bilayers 16, 17 and in sodium dodecyl sulfate (SDS). [18] [19] [20] The observation that certain mutations of the transmembrane helix of phospholamban not only disrupt the ability of the protein to form pentamers but also result in "superinhibition" of SERCA2a indicate that the monomeric, rather than the pentameric, form of phospholamban is responsible for inhibition of SERCA2a, with the pentamer likely representing an inactive reservoir. The inhibition of SERCA2a by phospho- Background Phospholamban is a reversible inhibitor of the Ca 2+ -ATPase of the cardiac sarcoplasmic reticulum (SR) and contributes to the regulation of heart muscle contractility. Because only the monomeric form, not the pentameric form, of phospholamban inhibits the Ca 2+ -pumping activity of the SR, it is important to understand the dynamic equilibrium between these 2 forms.
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The cardiac SR contains various phospholipids, including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), lysophosphatidylcholine (LPC), and lysophosphatidylethanolamine (LPE). 21 To clarify the roles of individual phospholipids as determinants of the equilibrium between the monomers and pentamers of phospholamban, we have now investigated the effects of various detergents and phospholipids on the oligomeric state of this protein.
Methods

Materials
Octaethylene glycol monododecyl ether (C12E8), noctyl--D-glucopyranoside (octylglucoside), Triton X-100, sodium deoxycholate (DOC), and SDS were obtained from Wako Chemicals (Osaka, Japan). Tetraethylene glycol monooctyl ether (C8E4), 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS); PC, PE, PS, and LPC from bovine brain; LPE from egg yolk; PI from soybean; and phosphatidic acid (PA) and phosphatidylglycerol (PG) from egg yolk lecithin were obtained from Sigma Chemicals (St Louis, MO, USA). Nonidet P-40 (NP-40) was from Nacalai Tesque (Kyoto, Japan), polyvinylidene difluoride membranes and hydroxyapatite Bio-Gel were from Bio-Rad (Hercules, CA, USA), and SP Sepharose fast-flow resin was from Amersham Pharmacia Biotech (Uppsala, Sweden). Mouse hybridoma cells that produce a monoclonal antibody to phospholamban (mAb A1) were kindly provided by J. Wang. 22, 23 
Preparation of Microsomes From Rabbit Heart
Cardiac microsomes enriched in SR were prepared as described previously 24 with some modifications. In brief, rabbit ventricular muscle was finely chopped and homogenized with a Polytron disrupter in 4 volumes of 10 mmol/L NaHCO3. The homogenate was centrifuged at 10,400 G for 20 min, and the resulting supernatant was filtered and then centrifuged at 60,400 G for 15 min. The pellet was suspended in a solution containing 0.6 mol/L KCl and 20 mmol/L imidazole-HCl (pH 6.7) and again centrifuged at 60,400 G for 15 min. The final pellet was washed and then suspended in a small volume of the same solution. Protein concentration was determined by the method of Lowry et al. 25 
Expression and Purification of Recombinant Phospholamban
Human phospholamban cDNA was amplified from a human heart cDNA library (Clontech, Palo Alto, CA, USA) by the polymerase chain reaction (PCR) and then cloned into pTrc-His-2B (Invitrogen, Carlsbad, CA, USA). The authenticity of the resulting plasmid was confirmed by 
Preparation of Mixed Micelles of Phospholipid and Detergent
Phospholipids dissolved in chloroform were evaporated by a stream of nitrogen gas. Various detergents at a concentration of 2% in a solution containing 0.2 mmol/L dithiothreitol, 150 mmol/L KCl, and 20 mmol/L Tris-HCl (pH 7.5) were added to the dried phospholipids to give a phospholipid/detergent weight ratio of 0.5. The mixture was then subjected to ultrasonic treatment at 4°C.
Analysis of the Oligomeric State of Phospholamban
Cardiac microsomes (0.3 mg/ml) or purified phospholamban (10 g/ml) were solubilized with 2% detergent or with mixed micelles containing 1% phospholipid and 2% deter- final concentration of SDS of 2%, 26 the samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on 15% or 10-20% gradient gels. The separated proteins were transferred electrophoretically to a polyvinylidene difluoride membrane at a constant current of 150 mA for 30 min at 4°C in a solution containing 25 mmol/L Tris, 193 mmol/L glycine, and 10% methanol. The membrane was then incubated at room temperature first with Trisbuffered saline containing 5% nonfat dried milk and 0.1% Tween 20 and then with mAb A1 in the same solution. Immune complexes were detected with horseradish peroxidase -conjugated secondary antibodies and enhanced chemiluminescence reagents (Amersham Pharmacia Biotech). The amount of phospholamban pentamer was quantitated by densitometry with a Lane and Spot Analyzer (Atto, Tokyo, Japan) and was expressed as a percentage of the value obtained for a sample maintained at 4°C with no detergent.
Statistical Analysis
Quantitative data are presented as means ± SE, unless indicated otherwise, and the significance of differences was determined with Dunnett's multiple comparison test. A pvalue of <0.05 was considered statistically significant.
Results
Effects of Various Detergents on Phospholamban in Cardiac SR
Most phospholamban molecules in the cardiac SR exist as pentamers that are stable after solubilization with SDS, whereas boiling in the presence of SDS induces complete dissociation of the pentamer into the monomer 18, 19 (Fig 1A) . Incubation of a microsomal fraction from rabbit heart at temperatures between 4.2°and 51.2°C had no substantial effect on the stability of the phospholamban pentamer in the presence of 2% SDS (Fig 1B,C) . Determination of the oligomeric state of phospholamban by SDS-PAGE and immunoblot analysis thus did not itself affect this parameter.
We then examined the effects of various detergents (CHAPS, octylglucoside, C12E8, C8E4, DOC, NP-40, Triton X-100) at a concentration of 2% on the oligomeric state of phospholamban in cardiac microsomes. Given that the sta- bility of the oligomeric state is dependent on temperature, we examined it at temperatures between 4.2°and 51.2°C. Of the detergents examined, CHAPS, like SDS, had no significant effect on the proportion of pentameric phospholamban (Fig 1D,E) . In contrast, octylglucoside induced significant dissociation of phospholamban pentamers into monomers at 4.2°C and dissociation was almost complete at temperatures >15°C (Fig 1H,I) . Triton X-100 had an effect similar to that of octylglucoside (data not shown). Other detergents, including C12E8 (Fig 1F,G) , C8E4, DOC, and NP-40 (data not shown) manifested an intermediate effect on the oligomeric state of phospholamban; significant dissociation of phospholamban pentamers was observed at temperatures of 40°C and higher in the presence of 2% C12E8. The detergents examined could thus be classified into 3 groups: CHAPS and SDS stabilize the pentameric form of phospholamban; octylglucoside and Triton X-100 are highly effective inducers of pentamer dissociation; and C12E8, C8E4, DOC, and NP-40 are moderately effective inducers of pentamer dissociation.
Effects of Various Detergents on Purified Phospholamban
Cardiac microsomes contain phospholipids and phospholamban-interacting proteins, including SERCA2a. We therefore next examined the direct effects of detergents on the oligomeric state of purified recombinant phospholam- ban, which is devoid of phospholipids and other proteins. Recombinant human phospholamban was expressed in E. coli and purified by sequential chromatography on hydroxyapatite, SP Sepharose, and an immunoaffinity column. We obtained essentially the same results on incubation of the purified phospholamban with various detergents as we did with phospholamban in cardiac microsomes (Fig 2) .
We examined the concentration dependence of the effects of 3 representative detergents on the oligomeric state of phospholamban. Incubation of purified phospholamban with various concentrations of octylglucoside or C12E8 at 37°C induced dissociation of the phospholamban pentamers into the monomers in a concentration-dependent manner (Fig 3) . Incubation of phospholamban with various concentrations of CHAPS, however, resulted in substantial dissociation of the pentamer only at 0.2% detergent, whereas higher concentrations of CHAPS stabilized the pentamer (Fig 3) . The critical micelle concentration of CHAPS is 0.2%. 27 CHAPS stabilized the pentameric form of phospholamban, although it induced pentamer dissociation at concentrations below the critical micelle concentration.
Effects of Phospholipids on Phospholamban in the Presence of CHAPS
To determine the abilities of various phospholipids to induce dissociation of the phospholamban pentamer, we examined the effects of the phospholipids on the oligomeric state of phospholamban in the presence of a pentamer-stabilizing detergent, CHAPS. Purified phospholamban (10 g/ml) was incubated with mixed micelles of phospholipid (1%) and CHAPS (2%) at temperatures between 4.2°a nd 51.2°C (Fig 4) . Of the 8 different phospholipids examined, only PA induced the dissociation of phospholamban pentamers into monomers; none of PC, PS, PI, PE, LPC, LPE or PG showed a significant effect on the amount of phospholamban pentamer in the presence of 2% CHAPS.
Effects of Phospholipids on Phospholamban in the Presence of Octylglucoside
To determine the abilities of phospholipids to stabilize the phospholamban pentamer, we examined their effects on the oligomeric state of phospholamban in the presence of octylglucoside, a highly effective inducer of pentamer dissociation (Fig 5) . Octylglucoside (2%) alone induced essentially complete dissociation of phospholamban pentamers into the monomers at temperatures >15°C (Figs 2,5A ).
Whereas PA (1%) had no effect on pentamer stability in the presence of 2% octylglucoside, the other 7 phospholipids examined partially inhibited pentamer dissociation induced by octylglucoside (Fig 5) . In addition, LPC, LPE, and PG significantly shifted the temperature dependence of octylglucoside-induced pentamer dissociation to higher temperatures (Fig 5) . Finally, we examined the effects of various concentrations of PC or LPC on the oligomeric state of phospholamban in the presence of 2% octylglucoside. The pentamer-stabilizing actions of PC and LPC and the shift in the temperature dependence of octylglucoside-induced pentamer dissociation observed in the presence of LPC were both concentration dependent (Fig 6) .
Discussion
Given that the monomeric form of phospholamban, but not the pentameric form, inhibits SERCA2a activity in cardiac SR, it is important to understand the dynamic equilibrium between these 2 states of the protein. We have now examined the effects of various detergents on the oligomeric state of phospholamban and found that CHAPS stabilizes the pentameric form whereas octylglucoside is a highly effective inducer of pentamer dissociation. Taking advantage of the properties of these 2 detergents, we further clarified the potential roles of phospholipids as determinants of the balance between the monomeric and pentameric forms of phospholamban. Among the 8 phospholipids examined, only PA had the ability to induce pentamer dissociation. The other phospholipids all stabilized the pentameric form Effects of phospholipids on the oligomeric state of phospholamban. Among the 8 phospholipids examined, PA was an effective inducer of pentamer dissociation, whereas the other phospholipids exhibited pentamer-stabilizing activity. LPC, LPE, and PG were highly effective stabilizers of the pentamer. The monomeric form, not a pentameric form, of phospholamban inhibits Ca 2+ -pumping activity of SERCA2a. The metabolism of phospholipids in cardiac SR may thus contribute to regulation of heart muscle contractility by shifting the equilibrium between monomers and pentamers of phospholamban (See text for abbreviations).
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of phospholamban. LPC, LPE, and PG were especially effective in stabilization of the pentamer (Fig 7) . These results indicate that the phospholipid environment plays an important role in determining the oligomeric state of phospholamban.
Mutations of phospholamban that disrupt the pentamer result in "superinhibition" of SERCA2a, 15 indicating that the monomeric form of phospholamban is the active inhibitory species, whereas the pentameric form may function as an inactive reservoir. An increase in the amount of PA in the SR membrane might thus induce dissociation of the phospholamban pentamer and inhibition of SERCA2a activity, resulting in a decrease in heart contractility (Fig 7) . In contrast, an increase in the abundance of LPC, LPE, or PG might increase heart contractility by stabilizing the pentameric form of phospholamban (Fig 7) . Furthermore, given that the mutations of phospholamban that enhance inhibition of SERCA2a by destabilizing the pentamer lead to cardiomyopathy and heart failure, 22 the phospholipid environment of phospholamban might also be a determinant of heart muscle function in pathological conditions.
In the present study, we used SDS-PAGE followed by immunoblot analysis to determine the oligomeric state of phospholamban. This approach is simple and reveals directly the amounts of both oligomeric and monomeric species in a given sample. SDS has previously been shown to stabilize the phospholamban pentamer. 18 Indeed, we found that SDS (2%) did not induce dissociation of the pentameric form of phospholamban at temperatures below 50°C and did not induce oligomerization of the monomer after incubation at room temperature for several hours (data not shown). The oligomeric state of phospholamban has been studied by spin-label electron spin resonance 16, 28 and by fluorescence energy transfer. 29, 30 In the former approach, the oligomeric state is indirectly estimated from the stoichiometry of lipid interaction with the protein. This method is informative for studies of the oligomeric state of phospholamban in lipid membranes but is not able to resolve the amounts of each oligomeric and monomeric species, instead providing the average state of oligomerization. Fluorescence energy transfer is useful for estimation of the oligomeric state of labeled phospholamban either in solution or in a lipid bilayer. However, no energy transfer was observed in SDS without boiling. This method revealed that ~50% of phospholamban is present as a monomer in SDS after boiling and that an oligomer of 9-11 monomers is predominant in dioleoylphosphatidylcholine lipid bilayers. 29 These results differ from those obtained by spin-label electron spin resonance 16 and by SDS-PAGE (this study). In our approach, the oligomeric state of phospholamban is visualized directly and can be analyzed under all conditions without labeling of lipids or the protein, although it is not able to provide a direct measurement of the oligomeric state in the natural environment of the SR membrane. In addition, the temperature-dependent analyses performed with this method allowed comparison of the abilities of phospholipids or detergents to induce dissociation or stabilization of the phospholamban pentamer.
We showed that PA is a highly effective inducer of dissociation of the phospholamban pentamer. An increase in the proportion of the phospholamban monomer results in increased inhibition of SERCA2a activity in cardiac SR. The PA content of the SR membrane might therefore be an important determinant of heart muscle contractility. Given that the abundance of PA in the cardiac SR membrane is normally low, 21 a small absolute increase in PA content might have a pronounced effect on heart muscle. PA is formed predominantly as a result of the hydrolysis of PC caused by the activation of phospholipase D (PLD), although it can be generated from various sources through the action of enzymes such as diacylglycerol kinase and glycerol-3-phosphate acyltransferase. Two isoforms of PLD are expressed in the heart. 31 The PLD1 isoform is localized to the endoplasmic reticulum, secretory granules, and lysosomal-endosomal compartment of various cell types, 32, 33 whereas PLD2 predominates in the plasma membrane. 34 PLD1 would therefore be expected to regulate the PA content of cardiac SR. The activity of PLD1 is itself regulated by small GTP-binding proteins, such as ADPribosylation factor and Rho family GTPases (RhoA, Rac1, Cdc42), as well as by protein kinase C-. 35 Both Rho and protein kinase C have been implicated in cardiac hypertrophy and heart failure. 36 Under these pathological conditions, the activation of PLD1 may increase the amount of PA in cardiac SR and thereby contribute to depression of cardiac function by increasing the proportion of the monomeric form of phospholamban and inhibiting SERCA2a activity.
